drugset / Trial / NCT02545751

SBRT Combined With Thymalfasin for Metastatic Esophageal Cancer

NCT02545751

Phase 2 Unknown 29 enrolled Hangzhou Cancer Hospital
NaSingle-groupOpen-labelTreatment

Summary

Patients with esophageal cancer that had metastatic lesions after been treated with definitive surgery or chemoradiotherapy are being asked to participate in this study. 1. To observe immunity-mediated tumor response after Stereotactic Body Radiation Therapy(SBRT) of a metastatic site in metastatic esophageal cancer patients. 2. To induce the efficacy (effectiveness) of a new combination of therapy, SBRT and thymalfasin for heavily pretreated, metastatic esophageal cancer patients; This study will help find out what effects (good or bad) the combination of radiotherapy and thymalfasin has on metastatic esophageal cancer.

Timeline

Start
2016-01
Primary completion
2017-12
Completion
2018-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Thymalfasin Peptide

Indications